Bern, August 31st, 2021. The last visit of the last NOSTONE participant took place today. The overall study treatment phase has been now completed, with 93% participants reaching end of study in compliance with the study protocol and only 7% drop outs or lost of view patients. The patients’ commitment to the study was exceptional and instrumental to the successful achievement of the trial, now entering the data analysis phase. The study results are awaited for early 2022.
